Even in APL, ATRA’s ability to activate RARs and induce leukemia cell differentiation can be uncoupled from its activity to induce PML-RARα degradation, inhibit APL stem cells, and treat APL20,21. This evidence concerns the gene RARS1 and acute promyelocytic leukemia.